Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Studies in the area of cancer gene therapy reported from INSERM
November 25th, 2008
Research findings, 'Phosphatidylinositol 3-kinase-dependent transcriptional silencing of the translational repressor 4E-BP1,' are discussed in a new report. "The suppressor of translation initiation 4E-BP1 functions as a key regulator in cellular growth, differentiation, apoptosis and survival. While the control of 4E-BP1 activity via phosphorylation has been widely studied, the molecular mechanisms and the signaling pathways that govern 4E-BP1 gene expression are largely unknown," scientists in France report. "Here we show that inactivation of phosphatidylinositol 3-kinase (PI3K) consequent to stable expression of the antiproliferative somatostatin receptor 2 (sst2) in...
Source: Cancer Weekly (2008-11-25)
|
